Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Authors	DONNELLY J. P. CHEN S. C. KAUFFMAN C. A. STEINBACH W. J. BADDLEY J. W. VERWEIJ P. E. CLANCY C. J. WINGARD J. R. LOCKHART S. R. GROLL A. H. SORRELL T. C.. BASSETTI M. AKAN H. ALEXANDER B. D. ANDES D. AZOULAY E. BIALEK R. BRADSHER R. W. BRETAGNE S. CALANDRA T. CALIENDO A. M. CASTAGNOLA E. CRUCIANI M. CUENCA-ESTRELLA M. DECKER C. F. DESAI S. R. FISHER B. HARRISON T. HEUSSEL C. P. JENSEN H. E. KIBBLER C. C. KONTOYIANNIS D. P. KULLBERG B. J. LAGROU K. LAMOTH F. LEHRNBECHER T. LOEFFLER J. LORTHOLARY O. MAERTENS J. MARCHETTI O.. MARR K. A. MASUR H. MEIS J. F. MORRISEY C. O. NUCCI M. OSTROSKY-ZEICHNER L. PAGANO L. PATTERSON T. F. PERFECT J. R. RÁČIL Zdeněk ROILIDES E. RUHNKE M. PROKOP C. S. SHOHAM S. SLAVIN M. A. STEVENS D. A. THOMPSON G. R. VAZQUEZ J. A. VISCOLI C. WALSH T. J. WARRIS A. WHEAT L. J. WHITE P. L. ZAOUTIS T. E. PAPPAS P. G.
Year of publication	2020
Type	Article in Periodical
Magazine / Source	Clinical Infectious Diseases
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://watermark.silverchair.com/ciz1008.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAArAwggKsBgkqhkiG9w0BBwagggKdMIICmQIBADCCApIGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM_tCdNIwNkMPbaqGKAgEQgIICY-MRWU8BzxG9L5hO1OjazR8yFcnzSS0UPCfJTfBpu_2wgG
Doi	http://dx.doi.org/10.1093/cid/ciz1008
Keywords	consensus; definitions; invasive fungal diseases; diagnosis; research
Description	Background Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. Methods To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. Results There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. Conclusions These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk. European Organization for Research and Treatment of Cancer and the Mycoses Study Group definitions for probable invasive fungal disease now include solid organ transplant, hematologic malignancy, graft-versus-host disease, the reverse halo sign, revised thresholds for galactomannan, Aspergillus polymerase chain reaction, and definitions for candidiasis, cryptococcosis, non-human immunodeficiency viirus-associated pneumocystosis, and endemic mycoses.